This case discusses U.S. policy to allow pharmaceutical companies to run direct-to-consumer drug ads. This is focused around a National Public Radio Planet Money podcast in which the journalists do a deep dive into how the United States became one of only two countries to allow direct-to-consumer drug ads, as well as the effects that this has on consumers. This case may be discussed from a variety of angles, including marketing, sales, and communications
